Sapienza P, Borrelli V, di Marzo L, Cavallaro A
Department of Surgery "Pietro Valdoni", University of Rome "La Sapienza", Policlinico Umberto I degrees , Viale del Policlinico 155, 00161 Rome, Italy.
Eur J Vasc Endovasc Surg. 2009 May;37(5):525-30. doi: 10.1016/j.ejvs.2009.01.012. Epub 2009 Mar 17.
This study aimed to determine whether the plasma levels of matrix metalloproteinases (MMPs)-2 and -9 and their specific inhibitors (tissue inhibitors of metalloproteinases (TIMPs-1 and -2)) were altered in patients with symptomatic and asymptomatic, severe, recurrent carotid artery stenosis.
Fifty-two patients (out of a total of 621) who had undergone successful carotid artery endarterectomy (CEA) between 1999 and 2003 and developed recurrent carotid artery stenosis (>/=70%) were included in the study. Restenosis was symptomatic in 23 patients and asymptomatic in 29 patients.
Recurrent carotid artery stenosis was classified based on presentation, and as early-intermediate (6 months to 3 years) or late (>3 years). A detailed clinical history was taken and two blood samples were drawn from each patient to determine plasma levels of MMPs and TIMPs along with other biological parameters. Recurrent stenosis was confirmed with computed tomographic angiography.
Patients with symptomatic restenosis had significantly (p<0.001) higher active MMP-2 and -9 plasma values and significantly (p<0.001) lower TIMP-1 and -2 plasma values when compared to patients with asymptomatic restenosis. Plasma concentrations of active MMPs were higher and TIMPs lower in patients affected with late recurrent stenosis as compared to early-intermediate restenosis (p<0.001). No differences were recorded in latent MMP plasma values. Multivariate analysis showed that active MMP-2 and -9 were independent predictors of late recurrent carotid artery stenosis (p<0.03 and p<0.001, respectively).
Higher plasma concentrations of active MMP-2 and -9 were associated with an increased risk of carotid restenosis with plaque recurrence.
本研究旨在确定有症状和无症状的重度复发性颈动脉狭窄患者血浆中基质金属蛋白酶(MMPs)-2和-9及其特异性抑制剂(金属蛋白酶组织抑制剂(TIMPs-1和-2))水平是否发生改变。
选取1999年至2003年间成功接受颈动脉内膜切除术(CEA)且发生复发性颈动脉狭窄(≥70%)的52例患者(共621例)纳入研究。23例患者的再狭窄有症状,29例患者无症状。
根据临床表现将复发性颈动脉狭窄分为早期-中期(6个月至3年)或晚期(>3年)。记录详细的临床病史,并从每位患者采集两份血样,以测定MMPs和TIMPs的血浆水平以及其他生物学参数。通过计算机断层血管造影术确认复发性狭窄。
与无症状再狭窄患者相比,有症状再狭窄患者的活性MMP-2和-9血浆值显著更高(p<0.001),而TIMP-1和-2血浆值显著更低(p<0.001)。与早期-中期再狭窄患者相比,晚期复发性狭窄患者的活性MMPs血浆浓度更高,TIMPs更低(p<0.001)。潜伏性MMP血浆值无差异。多变量分析显示,活性MMP-2和-9是晚期复发性颈动脉狭窄的独立预测因子(分别为p<0.03和p<0.001)。
活性MMP-2和-9的血浆浓度升高与颈动脉再狭窄伴斑块复发风险增加相关。